共 29 条
[1]
Kendler KS(1996)The National Comorbidity Survey: lifetime prevalence, demographic risk factors, and diagnostic validity of nonaffective psychosis as assessed in a US community sample Arch Gen Psychiatry 53 1022-1031
[2]
Gallagher TJ(2019)Lifestyle Intervedntion for weight Management in People with serious mental illness: a systematic review with Meta-analyses, trial sequential analyses, and Meta-regression analyses exploring the mediators and moderators of treatment effects Psychother Psychosom 88 350-362
[3]
Abelson JM(2014)Pharmacological strategies to counteract antipsychotic-induced weight gain and metabolic adverse effects in schizophrenia: a systematic review and meta-analysis Schizophr Bull 40 1385-1403
[4]
Speyer H(2007)Long-term persistence with orlistat and sibutramine in a population-based cohort Int J Obes 31 1567-1570
[5]
Jakobsen AS(2017)Effect of GLP-1 receptor agonist treatment on body weight in obese antipsychotic-treated patients with schizophrenia: a randomized, placebo-controlled trial Diabetes Obes Metab 19 162-171
[6]
Westergaard C(2018)Treatment of clozapine-associated obesity and diabetes with exenatide in adults with schizophrenia: a randomized controlled trial (CODEX) Diabetes Obes Metab. 20 1050-1055
[7]
Norgaard HCB(2017)Effect of Liraglutide treatment on prediabetes and overweight or obesity in clozapine- or olanzapine-treated patients with schizophrenia Spectrum disorder: a randomized clinical trial JAMA Psychiatry 74 719-728
[8]
Pisinger C(2018)Frequency and reasons for missed appointments of outpatient mental health care users in the uMgungundlovu district Curationis 41 1835-undefined
[9]
Mizuno Y(undefined)undefined undefined undefined undefined-undefined
[10]
ST A(undefined)undefined undefined undefined undefined-undefined